| answer text |
<p>On 23 August 2018 the Department wrote to all pharmaceutical companies that supply
the United Kingdom with prescription only or pharmacy medicines from, or via, the
European Union/European Economic Area, asking them to ensure they have a minimum of
six weeks’ additional supply in the UK, over and above their business as usual operational
buffer stocks, by 29 March 2019 in the unlikely the event that the UK were to leave
the EU without a deal.</p><p> </p><p>Since then, we have received very good engagement
from industry who share our aims of ensuring continuity of medicines supply for patients
is maintained and able to cope with any potential delays at the border that may arise
in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand medicines
for breast cancer patients are vitally important to many people in this country. However,
the Department recognises that through its medicines supply contingency programme,
it is requesting sensitive commercial information from pharmaceutical companies. To
reassure participating companies, we have committed to treating all information received
confidentially, securely and to using it only for the purposes of the Department’s
programme. That means not introducing information about a company, specific medicine
or their supply routes into the public domain.</p>
|
|
